Grade My Investments
HomeFree Stock Grades › LQDA

Liquidia Corporation (LQDA) Stock Grade

LQDA · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$3.0B
P/E Ratio
17.8
Revenue Growth (YoY)
+1031.2%
Net Margin
-43.5%
Return on Equity
Dividend Yield
None

About Liquidia Corporation's fundamentals

Liquidia Corporation is a pharmaceutical company with a market capitalization of $3.0 billion and a price-to-earnings ratio of 17.8, though this metric reflects an unprofitable company. The company experienced exceptional revenue growth of 1,031.2% year-over-year, indicating rapidly expanding sales, though it currently operates at a significant loss with a net margin of -43.5%. The company does not pay a dividend and reported a net loss in its latest annual statement, suggesting it is still in a growth or development phase as it scales its business.

Track LQDA free — no credit card required. Live grade + monthly AI report →